Synopsis
Synopsis
0
CEP/COS
0
VMF
0
FDA Orange Book
0
Canada
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2s)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile
2. Galvus
3. Nvp Laf237
4. Nvp-laf237
5. Vildagliptin
1. Vildagliptin
2. 274901-16-5
3. (2r)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
4. Vildagliptin (2r)-isomer
5. Schembl671629
6. Dtxsid301119534
7. Akos015969326
8. F78360
9. A819091
10. (2r)-1-[2-[(3-hydroxy-1-adamantyl)amino]-1-oxoethyl]-2-pyrrolidinecarbonitrile
11. (2r)-1-[2-[(3-oxidanyl-1-adamantyl)amino]ethanoyl]pyrrolidine-2-carbonitrile
12. (2r)-1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2-pyrrolidine Carbonitrile; (r)-1-(2-(((1r,3s,5r,7s)-3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile
13. Rel-(2r)-1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile
1. Jalra
2. Equa
| Molecular Weight | 303.4 g/mol |
|---|---|
| Molecular Formula | C17H25N3O2 |
| XLogP3 | 0.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Exact Mass | 303.19467705 g/mol |
| Monoisotopic Mass | 303.19467705 g/mol |
| Topological Polar Surface Area | 76.4 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 523 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:
as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:
- as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.
- in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 and 5. 1 for available data on different combinations).
Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:
- as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.
- in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 and 5. 1 for available data on different combinations).
Treatment of type II diabetes mellitus
Dipeptidyl-Peptidase IV Inhibitors
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release. (See all compounds classified as Dipeptidyl-Peptidase IV Inhibitors.)
Hypoglycemic Agents
Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)
A10BH02
A10BH02
A10BH02
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10B - Blood glucose lowering drugs, excl. insulins
A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors
A10BH02 - Vildagliptin
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
97
PharmaCompass offers a list of Vildagliptin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vildagliptin manufacturer or Vildagliptin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vildagliptin manufacturer or Vildagliptin supplier.
PharmaCompass also assists you with knowing the Vildagliptin API Price utilized in the formulation of products. Vildagliptin API Price is not always fixed or binding as the Vildagliptin Price is obtained through a variety of data sources. The Vildagliptin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A NVP-LAF237 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of NVP-LAF237, including repackagers and relabelers. The FDA regulates NVP-LAF237 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. NVP-LAF237 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of NVP-LAF237 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A NVP-LAF237 supplier is an individual or a company that provides NVP-LAF237 active pharmaceutical ingredient (API) or NVP-LAF237 finished formulations upon request. The NVP-LAF237 suppliers may include NVP-LAF237 API manufacturers, exporters, distributors and traders.
click here to find a list of NVP-LAF237 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A NVP-LAF237 DMF (Drug Master File) is a document detailing the whole manufacturing process of NVP-LAF237 active pharmaceutical ingredient (API) in detail. Different forms of NVP-LAF237 DMFs exist exist since differing nations have different regulations, such as NVP-LAF237 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A NVP-LAF237 DMF submitted to regulatory agencies in the US is known as a USDMF. NVP-LAF237 USDMF includes data on NVP-LAF237's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The NVP-LAF237 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of NVP-LAF237 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The NVP-LAF237 Drug Master File in Japan (NVP-LAF237 JDMF) empowers NVP-LAF237 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the NVP-LAF237 JDMF during the approval evaluation for pharmaceutical products. At the time of NVP-LAF237 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of NVP-LAF237 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a NVP-LAF237 Drug Master File in Korea (NVP-LAF237 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of NVP-LAF237. The MFDS reviews the NVP-LAF237 KDMF as part of the drug registration process and uses the information provided in the NVP-LAF237 KDMF to evaluate the safety and efficacy of the drug.
After submitting a NVP-LAF237 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their NVP-LAF237 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of NVP-LAF237 suppliers with KDMF on PharmaCompass.
A NVP-LAF237 written confirmation (NVP-LAF237 WC) is an official document issued by a regulatory agency to a NVP-LAF237 manufacturer, verifying that the manufacturing facility of a NVP-LAF237 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting NVP-LAF237 APIs or NVP-LAF237 finished pharmaceutical products to another nation, regulatory agencies frequently require a NVP-LAF237 WC (written confirmation) as part of the regulatory process.
click here to find a list of NVP-LAF237 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing NVP-LAF237 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for NVP-LAF237 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture NVP-LAF237 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain NVP-LAF237 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a NVP-LAF237 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of NVP-LAF237 suppliers with NDC on PharmaCompass.
NVP-LAF237 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of NVP-LAF237 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right NVP-LAF237 GMP manufacturer or NVP-LAF237 GMP API supplier for your needs.
A NVP-LAF237 CoA (Certificate of Analysis) is a formal document that attests to NVP-LAF237's compliance with NVP-LAF237 specifications and serves as a tool for batch-level quality control.
NVP-LAF237 CoA mostly includes findings from lab analyses of a specific batch. For each NVP-LAF237 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
NVP-LAF237 may be tested according to a variety of international standards, such as European Pharmacopoeia (NVP-LAF237 EP), NVP-LAF237 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (NVP-LAF237 USP).
